Abstract
Aim: To describe the treatment landscape and associated economic burden for myelodysplastic syndromein Japan. Methods: We studied nationwide retrospective claims data from 2008 to 2019. The study cohort was categorized into patients receivingtransfusion, erythropoiesis-stimulating agent, erythropoiesis-stimulating agent+transfusion, azacitidine, azacitidine +transfusion and others. Results: Our study found that theazacitidine+transfusiongroup had the highest medical cost and severity of disease compared withtheother groups. In those patients, healthcare resource utilization and thecosts of transfusions, including iron chelation therapy, increased medical costs. Conclusion: Our retrospective analysis provides a current snapshot of real-world treatment patterns and associated incremental economic costs of iron chelation therapy with thepresence of transfusions that drive an increase in total costs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
